1-11 of 11
Ohad S Bentur
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz
Journal: Blood
Blood (2024) 144 (Supplement 1): 3061.
https://doi.org/10.1182/blood-2024-203577
Published: 2024
Journal Articles

A Multicenter, Open-Label, Phase 3, Randomized Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients with Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper Phenotype

Kate Cwynarski, Eva Domingo Domenech, David Sidransky, Ohad S Bentur, Pier Luigi Zinzani
Journal: Blood
Blood (2024) 144 (Supplement 1): 3074.1.
https://doi.org/10.1182/blood-2024-203290
Published: 2024
Journal Articles

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Gary J. Schiller, Sascha A. Tuchman, Natalie Callander, Muhamed Baljevic, Adrianna C Rossi, Rami Kotb, Darrell J White, Nizar J. Bahlis, Heather J. Sutherland, Sumit Madan, Richard Leblanc, Christopher P. Venner, William I. Bensinger, Dane R. Van Domelen, Chris Zhang, Ohad S. Bentur, Brea Lipe
Journal: Blood
Blood (2022) 140 (Supplement 1): 10050–10053.
https://doi.org/10.1182/blood-2022-158011
Published: 2022
Journal Articles

Real-World Safety and Effectiveness of Selinexor-Based Regimens in Patients with Relapsed or Refractory Multiple Myeloma and Dialysis-Dependent Renal Impairment

Ohad S. Bentur, Dane R. Van Domelen, James Niblock
Journal: Blood
Blood (2022) 140 (Supplement 1): 12600–12602.
https://doi.org/10.1182/blood-2022-158060
Published: 2022
Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Sundar Jagannath, Thierry Facon, Ashraf Z. Badros, Moshe Levy, Philippe Moreau, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Iryna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Chris P. Venner, Mamta Garg, Mercedes Gironella Mesa, Artur Jurczyszyn, Tadeusz Robak, Monica Galli, Craig Thomas Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Veselina S Goranova Marinova, Jelena Sreten Bila, Eirini Katodritou, Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sebastian Grosicki, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3793.
https://doi.org/10.1182/blood-2021-146003
Published: 2021
Journal Articles

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Yael C Cohen, Mor Zada, Shuang-Yin Wang, Ohad S. Bentur, Evgeni Chubar, Amos Cohen, Noa Lavi, Hila Magen, Moshe Gatt, Miri Zektser, Merav Leiba, Galia Stemer, Tamir Shragai, Irit Avivi, Assaf Weiner, Ido Amit
Journal: Blood
Blood (2021) 138 (Supplement 1): 2725.
https://doi.org/10.1182/blood-2021-149701
Published: 2021
Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Muhamed Baljevic, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J. Bahlis, Darrell White, Christine I. Chen, Heather J. Sutherland, Sumit Madan, Richard Leblanc, Michael Sebag, Christopher P. Venner, William I. Bensinger, Noa Biran, Andrew DeCastro, Dane R. Van Domelen, Ohad S. Bentur, Chris Zhang, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Brea Lipe
Journal: Blood
Blood (2021) 138 (Supplement 1): 2751.
https://doi.org/10.1182/blood-2021-150998
Published: 2021
Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Darrell J White, Christine I. Chen, Muhamed Baljevic, Sascha A. Tuchman, Nizar J. Bahlis, Gary J. Schiller, Brea Lipe, Rami Kotb, Heather J. Sutherland, William I. Bensinger, Sumit Madan, Michael Sebag, Suzanne Lentzsch, Natalie S. Callander, Noa Biran, Christopher P. Venner, Richard Leblanc, Jorge Monge, Evgeni Chubar, Tamar Tadmor, Noa Lavi, Merav Leiba, Andrew DeCastro, Dane R. Van Domelen, Chris Zhang, Moran Mishal, Ohad S. Bentur, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Cristina J. Gasparetto
Journal: Blood
Blood (2021) 138 (Supplement 1): 2748.
https://doi.org/10.1182/blood-2021-148759
Published: 2021
Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Suzanne Lentzsch, Brea Lipe, Sascha A. Tuchman, Nizar J. Bahlis, William I. Bensinger, Michael Sebag, Heather J. Sutherland, Jorge Monge, Cristina J. Gasparetto, Muhamed Baljevic, Natalie S. Callander, Christopher P. Venner, Darrell J. White, Rami Kotb, Christine I. Chen, Gary J. Schiller, Sumit Madan, Richard Leblanc, Andrew DeCastro, Ohad S. Bentur, Jatin J. Shah, Dane R. Van Domelen, Michael G. Kauffman, Sharon Shacham, Noa Biran
Journal: Blood
Blood (2021) 138 (Supplement 1): 1651.
https://doi.org/10.1182/blood-2021-150232
Published: 2021
Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Nizar J. Bahlis, Shambavi Richard, Darrell J. White, Sebastian Grosicki, Christine Chen, Sosana Delimpasi, Heather J. Sutherland, Zvenyslava Maslyak, Michael Sebag, Maria Gavriatopoulou, Suzanne Lentzsch, Ajai Chari, Maryana Simonova, Ivan Spicka, Iryna Kriachok, Meletios A. Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Jr., Thierry Facon, Maria-Victoria Mateos, Michele Cavo, Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 1634.
https://doi.org/10.1182/blood-2021-146324
Published: 2021
Journal Articles

In Vitro Effects of the Novel Platelet αIIbβ3 Receptor Antagonist RUC-4 on the Verifynow Assays: Potential for Point-of-Care Monitoring of RUC-4 Therapy

Ohad S. Bentur, MD, Barry S. Coller, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 166.
https://doi.org/10.1182/blood-2019-124548
Published: 2019